RECAP: CAPA Called on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit.   “Today, millions of patients and families are increasingly impacted by high drug prices while some Big Pharma companies continue abusing the U.S. patent system through anti-competitive tactics that hurt American patients.  By allowing the […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Calls on Congress to Intervene as Courts Undermine the ‘Skinny Label’ Framework, Preventing Generic Competition While Drug Companies Profit Recently, the U.S. Court of Appeals for the Federal Circuit upheld the verdict in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., subjecting Teva to a $234 million judgment that includes […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Points To Patent Quality As Key To Ultimately Lowering Prescription Drug Prices In a recent op-ed as part of Patent Quality Week, CAPA Executive Director Matthew Lane outlined the ways in which the pharmaceutical marketplace is impacted by Big Pharma’s manipulation and abuse of the U.S. patent system. Particularly, Lane dives […]

Continue Reading

WHAT YOU NEED TO KNOW TUESDAY, JULY 20: The Coalition Against Patent Abuse (CAPA) is hosting a panel with the Public Interest Patent Law Institute highlighting how patent law can impact every American, particularly when it comes to high drug prices. The event will feature a discussion moderated by CAPA Executive Director Matthew Lane and include the […]

Continue Reading

WHAT YOU NEED TO KNOW The Coalition Against Patent Abuse’s Executive Director Matthew Lane penned an op-ed in Morning Consult recently on the need to address patent abuse and anti-competitive pricing tactics used by some major pharmaceutical companies. In his op-ed, Mr. Lane dives into the current imbalance between rewarding new drug innovations and competition from low-cost alternatives.  […]

Continue Reading

WHAT YOU NEED TO KNOW Have You Heard? The Coalition Against Patent Abuse (CAPA) is Fighting Against Anti-Competitive Tactics Used by Some Major Pharmaceutical Companies to Keep Competition Out, Prices High. In a mini-series called, “Spot-On Savings,” CAPA outlined how the U.S. Patent and Trademark Office (USPTO), through its inter partes review (IPR) process, can generate […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.   “It is no secret that many pharmaceutical companies today utilize loopholes within the patent system to extend their monopolies while expanding their profits. This white […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Releases Statement after AbbVie CEO Testifies Before the House Oversight and Reform Committee on Use of Anti-Competitive Tactics that Keep Drug Prices High: “CAPA applauds the Committee for its continued oversight on specific anti-competitive tactics that some big drug companies have engaged in over recent years. This patent gamesmanship […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Read the full story below: CAPA examined how the IPR process struck down a patent relating to the […]

Continue Reading

WHAT YOU NEED TO KNOW What The Next U.S. Patent and Trademark Office (USPTO) Director Could Mean For Drug Prices: As anticipation builds around who the next USPTO director will be, the Coalition Against Patent Abuse (CAPA) is highlighting the importance of making the right choice to tackle anti-competitive behavior that will help lower drug prices.  […]

Continue Reading